Xbrane Biopharma: Securing funding solution ahead of BsUFA - Redeye

Redeye comments on Xbrane following yesterday’s press release, which provided updates on a conditional financing solution and the FDA re-inspections of the company’s contract manufacturing facilities. Xbrane is approaching its BsUFA date next week, with the potential for a US approval of its ranibizumab biosimilar.

Länk till analysen i sin helhet: https://www.redeye.se/research/1130924/xbrane-biopharma-securing-funding-solution-ahead-of-bsufa?utm_source=finwire&utm_medium=RSS